




















Provides High Event-Free and Overall Survival in
Patients with Advanced Indolent B Cell Malignancies:
CALGB 109901
Thomas Shea,1 Jeffrey Johnson,2 Peter Westervelt,3 Sherif Farag,4 John McCarty,5
Asad Bashey,6 Luis Isola,7 Lee-Anne Baxter-Lowe,8 Michael Kelly,9 Kouros Owzar,2
Charles Linker,8 for the Cancer and Leukemia Group BCancer and Leukemia Group B conducted a phase II study to evaluate the safety and efficacy of a reduced-
intensity conditioning regimen with allogeneic transplantation to treat patients with recurrent low-grade
B cell malignancies. Patients over age 18 with a diagnosis of relapsed, chemotherapy-sensitive disease under-
went transplantation with a matched sibling donor, and conditioning with cyclophosphamide (1 g/m2/day 3)
and fludarabine phosphate (25 mg/m2/day  5). Graft-versus-host prophylaxis included cyclosporine or ta-
crolimus plus low-dose methotrexate. Forty-four evaluable patients with a median age of 53 and median
of 2 prior regimens were accrued. Sixteen patients had follicular non-Hodgkin lymphoma and 28 had histol-
ogies including 7 indolent B cell lymphomas, 4 mantle cell, 15 chronic lymphocytic leukemia (CLL), and 2 pro-
lymphocytic leukemia (PLL) patients. The 6-month treatment-related mortality (TRM) was 2.4% and 3-year
TRM was 9%. Three-year event-free and overall survival were 0.75 and 0.81 for the follicular patients, 0.59
and 0.71 for the CLL/PLL patients, and 0.55 and 0.64 for the other histologies. The incidence of grade II-IV
acute graft-versus-host disease (GVHD) was 29%, and extensive chronic GVHD was 18%. This report dem-
onstrates that allogeneic sibling transplantation with a reduced-intensity conditioning regimen is safe and ef-
ficacious for patients with advanced indolent B cell malignancies enrolled on a Cooperative Group study.
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The treatment of low-grade non-Hodgkin lympho-
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6/j.bbmt.2011.01.016response rates, but a generally accepted inability to in-
duce durable remissions and cure in the vast majority
of patients with advanced disease [1,2]. Chronic
lymphocytic leukemia (CLL), small lymphocytic
lymphoma (SLL), and prolymphocytic leukemia (PLL)
share similar characteristics as treatable but incurable
malignancies with conventional approaches [3]. Mantle
cell lymphoma is a more aggressive malignancy that
has recently demonstrated sensitivity and durable remis-
sions followinghigh-dose therapywith intensive chemo-
therapy regimens and transplantation [4-6]. These
approaches have produced encouraging results in this
disease and demonstrate improved progression-free
(PFS) and overall survival (OS) compared to conven-
tional chemotherapy regimens plus the anti-CD20 anti-
body rituximab when used as a component of initial
therapy.
As with its use in mantle cell lymphoma, the addi-
tion of rituximab to conventional regimens for indolent
lymphomas orCLLhas increased the response rate and
disease-free survival (DFS) in these diseases [3,7-9].
The addition of rituximab also led to an improvement1395
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therapy in 1 large study [10]. Additional treatments
such as 131Iodine tositumomab or 90Yttrium ibritumo-
mab tiuxetan–labeled anti-CD20 bound isotopes are
also effective, but not necessarilymore so than employ-
ing maintenance therapy with unlabeled anti-CD20
antibodies [11-14]. Although these improvements
have been gratifying for patients afflicted with these
malignancies, eventual progression to refractory
disease and death remains a problem [1,2].
Over the past 20 years, reports have emerged of the
value of high-dose therapy with transplantation in
treating these illnesses. Early studies with autologous
transplants were especially encouraging when the in-
fused marrow product was rendered tumor free by
PCR analysis after ex vivo purging with anti-CD20
antibodies [15-17]. Concerns remain about the risk
of late complications such as the emergence of
myelodysplasia or acute leukemia in patients treated
with this approach, and for a number of years, such
treatment had fallen out of favor [18-22]. Recent data
have suggested that the use of antibody-mediated
in vivo tumor cell purgingmight lead to long remissions
and possible cure without the high risk of treatment-
related complications associated with allogeneic trans-
plants, but the durability of these responses and the
long-term risks of secondary malignancies remain un-
certain [23-27].
Data have emerged from both registry and large,
single-institution studies that allogeneic donor trans-
plants, whether with an ablative or nonablative ap-
proach, can be associated with prolonged remission
and apparent cure for low-grade NHL patients
[28-36]. Reduced-intensity regimens have demon-
strated low morbidity and mortality rates associated
with these approaches even after relapse following an
autologous transplant [37-39]. As a result of these
encouraging single-institution results, Cancer and
Leukemia Group B (CALGB) undertook a prospective
multicenter trial for patients with relapsed low-grade
or mantle cell lymphoma, CLL, PLL, or SLL using
matched related donors and a reduced-intensity regi-
men [40]. The current report describes the results of
this phase II study with a single conditioning regimen,
GVHD prevention, and supportive care strategy.METHODS
Study Objectives
The primary objective of this trial was to demon-
strate a 6-month treatment-related mortality (TRM)
rate of\30% in a multicenter trial for patients with
low-grade NHL, CLL, and PLL. The secondary ob-
jectives of the trial were to measure the response rates
at 6 and 12 months posttransplant, the event-free sur-
vival (EFS), and OS of this study population and assessthe development of the total and T cell chimerism
rates in the peripheral blood and marrow at 30, 60,
90, and 180 days. Additional study endpoints included
determining the cumulative risk of acute and chronic
graft-versus-host disease (aGVHD, cGVHD), and
identifying other treatment-related toxicities such as
sinusoidal obstructive syndrome and duration of cyto-
penias. Classical definitions of GVHD were used, in-
cluding a designation of cGVHD as that which
occurred after day 100 [41].Patient Eligibility
All patients were\70 years of age, had histologi-
cally documented CLL, PLL, low-grade NHL, or
mantle cell lymphoma as follows. Diagnosis of CLL
was made according to the National Cancer Institute
(NCI) 1996 criteria [42]. Histologic documentation
of CLL or PLL required a lymphocytosis .5000/mL
with \55% prolymphocytes for CLL; patients
with $55% prolymphocytes were classified as PLL.
Histologic documentation of low-grade NHL was
made according to the Revised European–American
Classification of Lymphoid Neoplasms (REAL) sub-
types: SLL, follicular center lymphoma (grade I or
II), diffuse predominantly small cell type, or marginal
zone B cell. Patients must have failed at least 1 prior
regimen or have $3 of the International Prognostic
Index (IPI) risk factors; age.60;PS.1; lactatedehydro-
genase (LDH)more than normal; presence of.1 site of
extranodal disease; or stage III/IV disease. Diagnosis of
mantle cell lymphoma required histologic documenta-
tion with at least 1 of the following: immunophenotype
with expression of CD5 andCD19without CD23; cyto-
genetic analysiswithpresenceof t(11;14); overexpression
of cyclin D1, or bcl1 rearrangement.
All patients had stable or responsive disease to their
most recent treatment and were $4 weeks since prior
chemotherapy, radiation therapy, and surgery. Pa-
tients may not have received a prior autologous trans-
plant and not have symptomatic pulmonary disease,
uncontrolled diabetes mellitus, or serious infection.
All patients had a matched sibling donor by low-
resolution typing at HLA-A, -B, -DR.
All patients were staged with a physical exam, com-
puted tomography (CT) or positron emission tomog-
raphy (PET)/CT scan, bone marrow aspirate and
biopsy, and organ function testing. Laboratory values
included granulocytes $500/mL, platelets $50,000/
mL, calculated creatinine clearance $40 cc/min, total
bilirubin #3  ULN, AST #3  ULN, negative
u-HCG or serum HCG if of child-bearing potential,
carbon monoxide diffusing capacity (DLCO) .40%,
and left ventricular ejection fraction (LVEF) .30%.
Each participant signed an institutional review
board-approved, protocol-specific informed consent
in accordance with federal and institutional guidelines.
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Fludarabine was given at a dose of 30 mg/m2/day
on days27 through23. Cyclophosphamide was given
at a dose of 1 g/m2/day intravenous (i.v.) on days 25
through23. A target goal of 5-8 106matched sibling
donor peripheral blood CD341 cells were collected
following 4 or 5 days of granulocyte-colony stimulat-
ing factor (G-CSF) administration at 10 mg/kg/day
on days 25 to 22 or 21, and infused on day 0.
GVHD Prophylaxis and Assessment
GVHD prophylaxis consisted of tacrolimus on day
21 with tapering begun on day 190 as tolerated with
a goal of stopping by day 1150. The rate of taper was
adjusted for the presence of signs and symptoms of
GVHD. Tacrolimus was tapered more quickly (day
160 to day 190) if donor chimerism of CD3 cells
was\50% at day 160 or if disease progression oc-
curred. A competing risks model was used to simulta-
neously estimate the probabilities of acute or chronic
graft-versus-host disease (aGVHD, cGVHD) and
death. A similar competing risks model was used to si-
multaneously estimate the probabilities of acute
GVHD and death.
Donor Lymphocyte Infusion
Patients with progressive disease and no evidence
of GVHDwere tapered off tacrolimus at the time pro-
gressive or stable disease was noted. If there was no ev-
idence of active GVHD, then donor lymphocyte
infusions (DLIs) were given no sooner than 30 days af-
ter complete cessation of GVHD prophylaxis treat-
ment. The initial dose of DLI was 1  107 CD3
cells/kg. Subsequent doses of DLI could be given at in-
tervals of no less than 30 days in the absence of re-
sponse or GVHD with doses of 5  107 CD3 cells/kg.
Supportive Care
Antibiotic prophylaxis consisted of fluconazole,
acyclovir, and TMP/SMX per institutional standards.
Cytomegalovirus (CMV) monitoring and therapy
were based on positive cultures or PCR testing. G-
CSF was administered at a dose of 5 mg/kg/day from
day 15 until an absolute neutrophil count (ANC) of
.1000/mL was achieved for 3 consecutive days.
Study Monitoring and Statistical Design
Studymonitoring, data quality, and statistical eval-
uation were undertaken by the CALGB Statistical and
Data Management Centers. The primary endpoint of
the study was TRM within 6 months of the day of
stem cell infusion (day 0). The primary hypothesis
was that the probability of experiencing a TRM was
\30%. The null hypothesis, H0, that the TRM rate,
P, is #.15 (H0: P\ .15) was compared with the alter-
native hypothesis, HA, that P is $.30 (HA: P . 0.30).TRMwas assessed at 3 stages, with 15 patients accrued
per stage and a maximum of 45 patients entered onto
the study as long as the stopping criteria for the study
were not met. The significance level and power of this
design were 0.08 and 0.85, respectively. The time-to-
event distributions for OS and EFS were estimated us-
ing the Kaplan-Meier method, whereas the discrep-
ancy between 2 time-to-event distributions was
tested using the log-rank test.Chimerism Studies
Donor chimerism in peripheral blood as well as
CD19, CD3, and CD14/15 selected cells were deter-
mined using a polymerase chain reaction (PCR)-based
method that routinely achieved 1% sensitivity. CD19,
CD3, andCD14/15 cells were selected fromperipheral
blood mononuclear cells (PBMCs) using Miltenyi
magnetic particles (Miltenyi Biotec, Bergisch
Gladbach, Germany). The purity of each cell subset
was determined by flow cytometry. Two short tandem
repeat (STR) loci were amplified for each donor-
recipient pair (selected from VWF, D21S11, D18S51,
D16S539, PENTA D, D3S1358, FGA, D7S820,
D2S1338, D10S2325, D12S391, SE33, PENTA E).
Amplicons were separated using an automated nucleo-
tide sequencer (ABI 3100; Applied Biosystems, Foster
City, CA), and the quantity of each informative allele
from duplicate samples was determined using Gene-
Mapper fragment analysis software (Applied Biosys-
tems) [43].RESULTS
Patient Characteristics
Forty-seven patients from 13 different CALGB
transplant centers were registered onto this study
(Table 1). Three patients never began therapy and
are be included in this analysis of 44 patients who
were treated per protocol between August 2001 and
April 2006. Histologies included 16 follicular, 7 other
indolent B cell disease, 4 mantle cell, 15 CLL, and 2
PLL patients. Median time from diagnosis to trans-
plant was 2.5 years (range: 0.4-12.4 years). The median
number of prior therapies was 3 for the entire group
(range: 1-6) including a median of 3 for those patients
with CLL/PLL or mantle cell/other histologies and 2
prior therapies for the 16 patients with follicular NHL.
Four patients had received prior irradiation, and 1 of
27 NHL patients had an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status greater than
1. Forty-one percent of NHL patients had .1 site of
extra-nodal disease. The majority of patients had
either a short duration of initial remission, young age,
high-risk disease, or were transplanted following multi-
ple therapies.
Table 1. Patient Characteristics
47 Patients enrolled (44 evaluable)
Median age 53 years (range 39-68)
Male 80%
Caucasian 72%
Time from dx to SCT 2.5 years (0.4-12)
Elevated LDH 8/27 (30%)
Stage IV
>1 extranodal site 11/27 (41%) NHL pts
Histologies
NHL 27 pts (61%)
Follicular 16 pts (36%)
B cell 7 pts (16%)
SLL 3 pts
Marginal zone 3 pts
Malt 1 pt
Mantle cell 4 pts (9.1%)
CLL 15 pts (34.1%)
PLL 2 pts (4.6%)
Prior therapies
Prior treatment CLL/PLL Other B Cell/MC Follicular
# patients 17 11 16
# chemo regimens 3(1-5) 3 (1-6) 2 (1-3)
Immunotherapy 9 7 3
XRT 1 1 3
MC indicates mantle cell; CLL, chronic lymphocytic leukemia; PLL, prolymphocytic leukemia; pts, patients; NHL, non-Hodgkin lymphoma; LDH, lactate
dehydrogenase; SCT, stem cell transplantation; SLL, small lymphocytic lymphoma; XRT, external radiation therapy.
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Overall 6-month TRMwas 2.3% (1 subject) at day
117 from GVHD and sepsis indicating strong statisti-
cal evidence in support of the study hypothesis (Table
2). Three additional patients died of nonrelapse causes
at 18, 19, and 36 months from GVHD and sepsis for
a 3-year TRM rate of 9%. One additional patient
died of fungal pneumonia in conjunction with treat-
ment for cGVHD 7 years following transplant,
whereas another died of pancreatic adenocarcinoma
for an overall nonrelapse mortality (NRM) of 13.6%
after a minimum follow-up of 3 years. Twenty-five
percent (11 of 44) of patients experienced grade 4 non-
hematologic toxicities, primarily from infection orTable 2. Toxicities
Hematologic
Days ANC <1000/mL 8 (0-19)
Days plts <100,000/mL 12 (0-38)




Pulmonary embolus 1 (2%)
Veno-occlusive disease 1 (2%)








CMV indicates cytomegalovirus; ANC, absolute neutrophil count.
*More than 1 type of infection was seen in multiple patients.
†Two patients had CMV infection with pneumonia (1) or colitis (1) and 7
had viral reactivation requiring preemptive therapy.GVHD. Additional serious toxicities included 1 pul-
monary embolus, 1 grade 4 sinusoidal obstructive syn-
drome, and 2 second malignancies: 1 of the pancreas
and a second of the distal esophagus. The median du-
ration of an ANC\1000/mL was 8 days (range: 0-19)
and thrombocytopenia \100,000/mL was 12 days
(range: 0-38). Twenty-seven of the 44 patients re-
quired no platelet transfusions. The median number
of red cell transfusions during the transplant period
was 1 (range: 0-9), with 13 patients requiring no
RBC transfusions. Infectious complications were
documented in 67% of patients; viral infections in
32%, including CMV reactivation in 15% of patients
and CMV infection in 2 patients, bacterial in 41%,
and fungal in 20% of patients (.1 type of infection
was seen in multiple patients). An additional 30% of
patients had site-specific infections for which no or-
ganism was identified.Chimerism
As described in Table 3, the median % of periph-
eral blood donor T cell chimerism at days 30, 60,
and 180 were 88%, 94%, and 97%, respectively. Com-
parable values for unfractionated (lymphoid 1 mye-
loid population) peripheral blood chimerism at days
30, 60, and 180 were 80%, 85%, and 99%, respec-
tively. Although these median values were high, a
significant percentage of patients demonstrated a per-
sistent mixed chimerism picture out to day 180.
Greater than 90% peripheral blood donor T cells
was seen in 45%, 61%, and 64% of patients at days
30, 60, and 180 posttransplant. Likewise, .90% un-
fractionated peripheral blood donor chimerism was
Table 3. Chimerism
Day post-transplant 30 60 180
T cells
# pts with > 90% donor cells 45% 61% 64%
median % donor cells 88% 94% 97%
Unfractionated whole blood cells
# pts with > 90% donor cells 26% 36% 65%
median % donor cells 80% 85% 99%
Figure 2. Overall Survival: 44 evaluable patients and 14 deaths by dis-
ease histology: Follicular, n5 16/3 deaths; B Cell/Mantle Cell, n 5 11/4
deaths; CLL/PLL, n 5 17/7 deaths.
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and 180, respectively (Table 3). Thus, if full donor chi-
merism was defined as .90% donor cells, then 64%
and 65% of patients showed full donor engraftment
in the unfractionated and lymphoid compartments, re-
spectively, by 6 months. Bone marrow and peripheral
blood gave similar chimerism results at each time
point. Finally, no correlation was observed between
chimerism status and relapse.GVHD
The overall incidence of grades I-IV aGVHD was
61%, of which 11% was grade II, 16% grade III, and
2.3% grade IV. A total of 29.3% of patients experi-
enced limited and 18% had extensive cGVHD.EFS and OS: Figures 1 and 2
EFS is defined as time to progression or death be-
cause of any cause (Table 4). There have been 18
events. Twelve patients have relapsed at 3 (3 patients),
4 (1 patient), 6 (2 patients), 9 (1 patient), 15 (2 patients),
20 (1 patient), 29 (1 patient), and 45 (1 patient) months
posttransplant. The other 6 events were deaths in the
absence of relapse because of GVHD (2), sepsis (2),
fungal pneumonia in the setting of cGVHD (1), and
adenocarcinoma (1). Atlhoughmost patients with lym-
phoma achieved optimal response within the first 3Figure 1. Event-Free Survival for 44 evaluable patients and 18 deaths
or episodes of progressive disease by disease histology: Follicular, n 5
16/4 events; other B cell/mantle cell, n 5 11/5 events; and CLL/PLL,
n 5 17/9 events.months posttransplant, the CLL/PLL cohort demon-
strated a slower pace of response with the median time
to CR being 3.5 months, but 1 patient reported as re-
quiring 9 months and another 22 months posttrans-
plant. Six of 17 patients with CLL/PLL, 3 of 16 with
follicular, and 3 of 11 patients with other indolent B
cell malignancies have relapsed. Four patients received
DLI for progressive disease and subsequently died of
their malignancy. The other relapsed patients were
felt to be ineligible for DLI either because of uncon-
trollable relapse or preexisting GVHD. One addi-
tional patient received DLI for a stable partial
response and 1 for loss of chimerism. Both remain in
complete remission more than 4 years posttransplant.
For the 30 patients still alive, the median follow-up
is 4.6 years. The EFS at 3 years for follicular patients
was 0.75 (0.46-0.90), compared to 0.59 (0.33-0.78)
for CLL/PLL and 0.55 (0.23-0.78) for the other and
mantle cell histologies combined (Figure 1). Fourteen
deaths have occurred from progressive disease (7), in-
fection and GVH (6, 1 of which occurred following
a second transplant for relapsed disease), and a second
malignancy (1). OS at 3 years is 0.81 (0.51-0.93) for the
follicular histologies, 0.71 (0.43-0.87) for CLL/PLL,
and 0.64 (0.30-0.85) for the other and mantle cell his-
tologies, respectively (Figure 2).DISCUSSION
Despite the recent advances in standard therapies,
treatment outcomes for patients with indolent B cell
malignancies remain suboptimal, as life expectancies
are clearly reduced by these diagnoses [1-10,14,25].
For those patients who are seeking a cure, stem cell
transplantation has been available for many years,
although late recurrences and the development of
secondary myelodysplasia have undermined the utility
of autologous transplants, whereas treatment-related
Table 4. Outcomes
Follicular CLL/PLL Other/MC
# 16 17 11
3-year event-free survival 0.75 (0.46-0.90) 0.59 (0.33-078) 0.55 (0.23-0.78)
3-year overall survival 0.81 (0.51-0.93) 0.71 (0.43-0.87) 0.64 (0.30-0.85)
Disease progression 3 6 3
Death 3 7 4
MC indicates mantle cell; CLL, chronic lymphocytic leukemia; PLL, prolymphocytic leukemia.
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limited the use of allogeneic transplants [15-17,22].
Recently, the use of reduced-intensity regimens has
markedly reducedearlymorbidity andmortality follow-
ing allogeneic transplantation [32-34,44-48]. Although
early relapse and later complications of cGVHD and
infection remain a problem, the overall success with
these reduced-intensity regimens have all indicated
a plateau on the survival curves with 4-year or longer
disease-free remission rates exceeding 60% for
chemotherapy-responsive patients [32,35,36,44]. The
data from Khouri et al., is especially encouraging with
the use of transplant and high-dose rituximab, as the
PFS in that trial exceeded 80% at 5 years with a very
low incidence of aGVHDand cGVHD formatched re-
lated transplant patients [36]. A treatment regimen in-
cluding the identical schedule and dosage of rituximab
is currently being evaluated in a multicenter trial spon-
soredby an intergroup collaborationbetween theBlood
and Marrow Transplant Clinical Trials Network
(BMT-CTN), CALGB, ECOG, and Southwest On-
cology Group (SWOG).
In the current report, the fact that a multicenter
groupwas able to conduct an allogeneic transplant study
that yielded excellent outcomes with only a 2.3% 6-
month TRM was very encouraging. Recent mortality
rates from other trials are similar, but at the time the
study was planned, there was no CooperativeGroup ex-
periencewith reduced-intensity allogeneic transplant on
which to base an expectation of TRM [28,33,34].
Morbidity was also low, with an overall incidence of
grade IV nonhematologic toxicities of 25%, including
an 11% incidence of pulmonary complications that
consisted of pneumonitis, infection, and alveolar
hemorrhage. Severe hepatic and renal toxicities were
rare, and the overall incidence of infections included
5% CMV infection and 15% reactivation, 41%
bacterial, and 20% documented fungal processes.
The overall incidence of grade II-IV aGVHD was
29%. Thirty percent of patients had limited and 18%
had extensive cGVHD. Although these numbers are
somewhat higher than those reported by groups that
have used alemtuzamab as a component of the condi-
tioning regimen, reactivation of CMV is less frequent,
and the need for donor lymphocyte infusion for relapse
appears lower in the current study [32,39,44]. At day
30 posttransplant, only 26% of patients demonstrated.90% unfractionated peripheral blood donor
chimerism, and 45% demonstrated .90% T cell
donor chimerism. By day 180, the % of patients with
.90% unfractionated and T cell donor chimerism had
increased to 65% and 64%, respectively. At the same
time points, the median percentage of donor T cell
chimerism was higher and reached 85% and 94% by
day 60, and 99% and 97% by day 180. Thus, although
the median % of donor cells is high in both the
myeloid and lymphoid compartments by day 180, only
about 2 of 3 of patients achieved full donor chimerism
in both components of the peripheral blood by as late
as 6 months following transplant. If the approach
encouraged by Thomsen and colleagues [44] was fol-
lowed, this could lead to donor lymphocyte infusions
for as many as 1 of 3 of the patients, even in the absence
of disease progression. Peripheral blood and marrow
values correlatedwell with one another. The lack of cor-
relation between relapse and chimerism status may re-
flect small numbers of patients in our study or
alternatively, indicate that partial chimerism may in
fact be sufficient to maintain an antitumor effect while
associated with a low rate of long-term GVHD in
most patients. Our results are somewhat different from
the report by Thomson et al., where relapse was lower
in those patients who converted from partial to full do-
nor chimerism after DLI infusions compared to those
who remained with a mixed chimerism status despite
DLI. They also reported a higher remission and durable
remission rate in those relapsed patients who received
DLI than we observed, perhaps because of earlier inter-
vention at a time of less advanced disease. Alterations in
the immunosuppression regimens used or early infusion
of DLImight enhance the rate and frequency of full do-
nor chimerism, but one would expect this to be associ-
ated with an increased rate and severity of GVHD.
Despite these concerns, theThomson et al., results were
excellent, with 76% of patients remaining progression-
free at 4 years, with only 18% having extensive cGVHD
[44]. There were 14 deaths reported to date in the
CALGB study including 9 in patients who had relapsed
and required additional therapy. One patient died from
a pancreatic cancer, 2 years posttransplant. Five patients
died of infection related to GVHD at 4, 18, 19, 36, and
72 months posttransplant.
Significant challenges remain to the successful
application of this approach. Although the use of
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impact in recent reports of transplant studies for acute
leukemia, data on approaches using suchdonors in low-
grade malignancies is just emerging. Recent reports by
the EBMT andCIBMTR have indicated that although
use of unrelated donors resulted in a somewhat higher
incidence of aGVHD and cGVHD, the overall rates of
progression, morbidity, and mortality compare favor-
ably to outcomes following fully ablative transplants
[33,45]. It is notable, however, that the recent article
by Thomson et al., reported higher rates of PFS in
their matched related than in unrelated patients, even
with a reduced-intensity regimen. Although 53 is
relatively old for allogeneic transplants, it is young
for low-gradeNHLandCLLpopulations and in future
trials, one would anticipate an even higher median age
and likely a higher morbidity and mortality rate.
Whether the relapse rate could be reduced further by
more intensive therapy remains a question to be con-
sidered given the high rate of toxicity and low success
rate associated with frank relapse followed by DLI in
the current study [48,49]. Of the 6 patients who
received DLI, 4 died from progressive disease despite
the onset of significant GVHD, whereas the 2
patients infused with DLI for loss of chimerism and
stable partial remission remain in CR more than 2
years beyond DLI infusion. This suggests that careful
monitoring for relapse and early use of DLI may be
a more effective strategy than delaying such efforts
until frank recurrence is observed [44,50].
Although the number of enrolled patients with
low-grade NHL or CLL are less than in the Khouri
or Thomson trials, our results are remarkably similar,
especially for the follicular lymphoma patients
[36,44]. Even in more aggressive diseases such as
PLL or mantle cell lymphoma, there appears to be
a plateau on the EFS curves, albeit with median
follow-up that remains less than 4 years. Although
the number of patients is small, we have only had 1 pa-
tient relapse beyond 2 years in this study, suggesting
that most responses will be durable. This is consistent
with the results published by theM.D. Anderson group
in which nonablative allogeneic transplant appeared to
confer a higher likelihood of prolonged DFS in mantle
cell patients, especially in those with relapsed or refrac-
tory disease, compared to what had been achieved with
autologous transplantation [51]. Also of note is the pro-
longed time to best response that can be seen in these
patients, particularly those with CLL. This likely re-
flects in part the slow time to establishing full donor
chimerism, which is associated with the graft-versus-
leukemia effect that is known to occur in these patients
but which can take months to develop.
Our results testify not only to the efficacy of this
approach, but confirm that this treatment can be un-
dertaken safely and effectively in a large number of
transplant centers by following rigorous protocols.These outcomes should reassure the oncology com-
munity that this is a viable and potentially curative
strategy for otherwise healthy patients with advanced,
but still chemosensitive disease, or those demonstrat-
ing progressively shorter durations of response to stan-
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